CHO-plus

Founded in 2014, CHO Plus addresses capacity constraints and high costs in biopharmaceutical manufacturing through proprietary cell line engineering. The company's technology platform creates GMP-compliant CHO and HEK-293 cell lines with dramatically enhanced productivity for monoclonal antibodies and AAV vectors. CHO Plus operates as a technology licensor, planning to generate revenue through royalties from biopharma partners using their engineered cell lines in commercial manufacturing processes.

Patented genetic engineering technologies for creating highly productive mammalian cell lines (CHO and HEK-293) with up to 10-fold increases in protein production and over 15-fold improvements in AAV vector yields, coupled with screening technology that identifies high-producing clones more efficiently.

CHO Plus competes with established CDMOs like Lonza and WuXi Biologics, as well as cell line developers like Selexis and ATUM. Their differentiation includes demonstrated 10x productivity improvements (vs. typical 2-5x for competitors), focus on both protein and viral vector production, and technology designed as drop-in replacements for existing manufacturing processes.